Exploring Small-cap Biotech ETFs: 5 Specialized Funds for Targeted Healthcare Investing

Exchange-traded funds have revolutionized how investors access sector opportunities without concentrating risk in individual stocks. When it comes to biotech ETFs, particularly those focusing on smaller-cap companies, the advantages become even more pronounced. These investment vehicles allow you to gain diversified exposure across emerging and niche biotech opportunities, hedge different market conditions, and capitalize on specific healthcare trends—all through a single fund. This guide explores five specialized small-cap biotech ETFs selected based on data as of February 9, 2026, each offering distinct strategic approaches to biotechnology investing.

Why Small-cap Biotech ETFs Matter for Modern Investors

The biotech sector continues to evolve, driven by breakthroughs in gene editing, FDA approvals for novel therapies, and growing investor interest in precision medicine. Small-cap biotech ETFs provide several critical advantages. First, they democratize access to emerging companies that might otherwise require significant individual research to evaluate. Second, they offer structural advantages over single-stock investing—if one company faces setbacks, the impact on your overall portfolio remains limited. Third, for those comfortable with additional leverage or inverse strategies, these specialized funds enable both long and short positioning in the biotechnology space. The funds highlighted below were selected based on assets under management (AUM) under $100 million as of the reference date, ensuring a focus on truly specialized offerings.

Aggressive Growth Strategies: Leveraged Exposure to Biotech Upside

1. ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ:BIB)

AUM: US$89.54 million

For investors with bullish near-term convictions about biotech, this fund—established in April 2010—delivers two times daily long exposure to the broad NASDAQ Biotechnology Index. This leverage amplifies gains when the index rises, making it appealing for traders with active strategies. However, this leveraged design carries important caveats. The fund’s structure isn’t suited for buy-and-hold investors or those with conservative risk tolerances, as leverage decay can erode long-term returns during sideways or volatile markets.

BIB holds 263 positions across the biotech landscape. Its heaviest allocations include Gilead Sciences (NASDAQ:GILD) at 6.78%, Amgen (NASDAQ:AMGN) at 6.23%, and Vertex Pharmaceuticals (NASDAQ:VRTX) at 6.17%—representing a well-diversified mix of established biotech leaders. The fund’s broad index approach ensures exposure across multiple therapeutic areas and company stages.

2. Direxion Daily S&P Biotech Bear 3x Shares (ARCA:LABD)

AUM: US$68.18 million

This fund represents the inverse side of biotech ETF strategies. Rather than holding individual stocks, LABD tracks three times the inverse daily return of the S&P Biotechnology Select Industry Index. In practical terms, the fund gains value when the biotech sector weakens and loses value when it strengthens. This leveraged inverse vehicle is explicitly designed for short-term tactical hedging or bearish views, not long-term holding strategies.

Unlike traditional equity-based ETFs, LABD achieves its objectives through financial derivatives such as futures contracts. This distinction matters operationally—the fund experiences different risk dynamics than stock-based peers. Its high leverage and directional bet make it suitable only for experienced traders managing specific downside hedges or short-term tactical positions.

Thematic Biotech Focus: Precision Healthcare Opportunities

3. Tema Heart and Health ETF (NASDAQ:HRTS)

AUM: US$56.55 million

Launched in November 2023, this fund illustrates how biotech ETFs can target specific disease areas and treatment modalities. HRTS focuses on companies developing solutions for diabetes, obesity, and cardiovascular disease—sectors energized by breakthrough medications and expanded patient populations. The fund has undergone strategic rebranding, most recently from GLP-1 Obesity and Cardiometabolic ETF to reflect its broader therapeutic mandate.

The fund manages 46 holdings with approximately 75% in large-cap stocks and 22% in mid-cap positions, tilting more established than pure small-cap portfolios. Geographic concentration favors US-listed companies at roughly 75%. Leading positions include Eli Lilly and Company (NYSE:LLY) at 10.04%, Roche Holding (OTCQX:RHHBY, SWX:ROG) at 5.42%, and Johnson & Johnson (NYSE:JNJ) at 4.8%—reflecting both pure-play biotechs and diversified healthcare companies with relevant product franchises.

4. Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

AUM: US$51.53 million

For investors betting on the genomics revolution, GNOM provides targeted exposure through the Solactive Genomics Index. This fund captures companies engaged in gene editing, genomic sequencing, genetic medicine, and computational genomics—sectors many expect to drive transformative healthcare outcomes over the coming decades. Approximately 90% of holdings reside in pharmaceuticals, biotechnology, and life sciences sectors.

GNOM’s portfolio of 50 companies includes Moderna (NASDAQ:MRNA) at 6.33%, Arrowhead Pharmaceuticals (NASDAQ:ARWR) at 6.14%, and Praxis Precision Medicines (NASDAQ:PRAX) at 5.98%. This concentrated but specialized approach attracts investors seeking precision exposure to genomics-driven innovation rather than broad-based sector participation.

Conservative Biotech Strategy: FDA-Approved Product Focus

5. Virtus LifeSci Biotech Products ETF (ARCA:BBP)

AUM: US$44.8 million

Among the five funds presented, BBP represents the most conservative biotech ETF strategy. Launched in December 2014, it tracks the LifeSci Biotechnology Products Index, concentrating exclusively on US-listed biotech companies with at least one FDA-approved drug therapy in their portfolios. This filtering criterion removes early-stage risks, favoring companies that have cleared regulatory hurdles and generated or are generating commercial revenue.

The fund employs equal-weighted holdings rebalanced semi-annually, ensuring that smaller companies receive proportionate capital allocation alongside larger peers. Top holdings include ImmunityBio (NASDAQ:IBRX) at 3.98%, Mirum Pharmaceuticals (NASDAQ:MIRM) at 2.40%, and Moderna (NASDAQ:MRNA) at 2.16%. This diversified approach across proven commercial-stage biotech provides a middle path between aggressive leverage and thematic concentration.

Selecting Your Biotech ETF Strategy

The five small-cap biotech ETFs outlined above serve distinctly different investor objectives. Aggressive traders comfortable with daily rebalancing and leverage may favor BIB’s amplified exposure or LABD’s downside hedging capability. Investors convinced of specific healthcare breakthroughs—whether in obesity treatment or gene medicine—might gravitate toward HRTS or GNOM’s thematic focus. Conservative investors preferring to limit early-stage company risk would find BBP’s FDA-approved product mandate more appropriate.

When evaluating any biotech ETF, consider your time horizon, risk tolerance, market outlook, and conviction level regarding specific therapeutic areas. The biotech sector’s rapid evolution means these specialized funds continue to evolve their mandates and holdings. Before investing, review the most current prospectus and holdings data to ensure alignment with your investment goals. Small-cap biotech ETFs can serve as powerful tools for sector participation when selected thoughtfully.